Here are the 10-K annual reports from Indaptus Therapeutics, Inc. (INDP) in our archive since June 2025, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-K covers the audited annual report, with the full financial statements, so if you follow INDP and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full INDP filings page.
Indaptus Therapeutics reports a transformative year marked by a recapitalization, governance changes and a halt to clinical development. On December 22, 2025 it sold 300,000 Series AA and 700,000 Series AAA preferred shares to David E. Lazar for $6.0 million, each share priced at $6.00. These series are convertible into a combined 111,000,000 common shares, and Mr. Lazar is now the beneficial owner of about 96.4% of the company’s common stock on an as-converted, fully diluted basis.
Stockholders approved a large increase in authorized common shares to 1,000,000,000, a reverse stock split range, and board changes that installed multiple Lazar designees. The company repriced roughly 1.68 million warrants to an exercise price of $1.75 per share and used ATM sales, a $5.7 million convertible note, equity lines and several 2024–2025 equity/warrant financings to raise cash.
Indaptus, a clinical-stage immunotherapy developer, discontinued enrollment in its Decoy20 monotherapy and combination trials and has no current plans to start new clinical studies. It discloses substantial doubt about its ability to continue as a going concern and is evaluating a strategic transaction to invest in or acquire a target company.